BTIG Downgrades Neogenomics (NEO) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016
July 26, 2016 7:00 AM EDTFT. MYERS, Fla., July 26, 2016 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2016.
Second Quarter 2016 Highlights:
159% increase in consolidated revenue to record $63.1 million 158% increase in clinical genetic testing volume(1) Net income of $413,000 versus net loss of $176,000 in Q2 2015 281% increase in Adjusted EBITDA(2) to $9.2 million Diluted EPS of ($0.07) per share and Adjusted Diluted EPS(2) of $0.04 per shareConsolidated... More
